EOLS
Evolus, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$9.30
+2.76%Aug 5, 2026, 20:05 UTC
Evolus, Inc. announced its financial results for the second quarter ended June 30, 2026, reporting strong performance and its third consecutive quarter of positive adjusted EBITDA.
Aug 4, 2026, 12:30 UTC
Evolus expanded its partnership with Symatese by amending their licensing and distribution agreement to gain exclusive rights to commercialize the Estyme injectable hyaluronic acid gels in Canada, Australia, and New Zealand.
Source:Jul 10, 2026, 20:05 UTC
Evolus granted 115,000 restricted stock units to 38 newly hired non-executive employees as inducement awards under Nasdaq Listing Rule 5635(c)(4).
Source:Jul 8, 2026, 13:00 UTC
Evolus announced an exclusive licensing and distribution agreement with IBSA to develop and commercialize Profhilo in the United States.
Source: